News >

Combinations Key to Advances With Bone-Targeting Agents in mCRPC

Gina Columbus @ginacolumbusonc
Published: Thursday, Mar 09, 2017

John C. Araujo, MD, PhD

John C. Araujo, MD, PhD

Radium-223 dichloride (Xofigo) remains the sole radiopharmaceutical that benefits patients with metastatic castration-resistant prostate cancer (mCRPC) from both a skeletal-related event (SRE) and overall survival (OS) perspective.

State of the Science Summit on Genitourinary Malignancies. In an interview, he went into further detail about these radiopharmaceuticals and what the field can accomplish with them over the next year.

OncLive: What were the key takeaways from your discussion on bone-targeting agents in mCRPC?

Araujo: The main points that will be made for the oncologists that I’d like them to take home will be, first, that the greatest morbidity and mortality from prostate cancer is from metastatic disease to the bone. The current agents available that do target bone decrease the number of SREs, which would mean fractures, increase in pain, and spinal cord compression. Two of the agents, zoledronic acid and denosumab, decrease the number of SREs, but do not increase OS in these patients.

However, radium-223 did decrease the number of SREs and increase OS. These are the current FDA-approved agents in prostate cancer that target bone.

We’ve known about radium-223 for some time now. Is there any new data on the treatment?

There have been interesting combinations performed with chemotherapy, AR-antagonists, and AR-pathway blocking agents. Therefore, to see results with those combinations will be interesting in the future, as radium-223 solely targets bone—as far as we are aware. By combining these agents, one might be able to increase survival by targeting not only spread to bone, but also spread to other organs such as the liver and lungs.

Is there any rationale to develop newer-generation radiopharmaceuticals?

There are none that I am aware of. Currently, on the periodic table using that group of elements, I do not see any other agents being tested now at this time. There are a few older elements, including Strontium-89 and Samarium-153; however, they have fallen a little out of favor in prostate cancer with the approval of radium-223.

Why is bone metastasis incidence so high in mCRPC? Is there something with the tumor biology?

That is something that we have been working on for some time. Clearly, everyone does realize that prostate cancer does have a proclivity to go to bone. That’s the most fundamental problem with the disease after it spreads. It is also the most costly in terms of money, as well as cost in life, due to prostate cancer. However, it’s unclear what is actually in the bone marrow that either attracts the disease or that prostate cancer likes to go there, to find something that it needs, to survive. No direct signal has been confirmed as of yet.

If you were giving a talk on bone-targeted agents 1 year from now, what questions do you hope we will have answered by that time?

Since we are seeing an increase in the number of liver hepatic metastases, I am hoping that over the next year we will determine whether combination therapies that target the bone, as well as possibly the AR, would be more beneficial in these patients and increase OS.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication